GlassScriptPhysician profile
Jacqueline Carreno
NPI 1831266535
$15,414.56
in general payments reported to CMS, 2019-2025
46 companies · $2,439 in 2025
The $2,439 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $1,188 · 2021: $2,953 · 2022: $2,703 · 2023: $2,316 · 2024: $3,187 · 2025: $2,439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,528 · Consulting Fee: $1,250 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,527.83 |
| Consulting Fee | $1,250.00 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $2,091.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $1,669.13 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals LP | $1,200.83 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Amgen INC. | $1,157.76 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,134.53 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $1,042.86 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Bayer Healthcare Pharmaceuticals INC. | $747.81 | 2021-2025 | |
| Novo Nordisk INC | $727.10 | 2020-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $660.65 | 2019-2022 | |
| Horizon Therapeutics Plc | $652.46 | 2019-2022 | |
| Esperion Therapeutics, INC. | $545.80 | 2020-2025 | Nexletol |
| Ironwood Pharmaceuticals, INC | $451.45 | 2020-2025 | Linzess |
| Astellas Pharma US INC | $429.51 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $398.05 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.07 | 2021-2025 | Jardiance |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Carreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.